Description: The standard of care for jaundice needs to be revisited to better manage pre-discharge , outpatient, NICU admissions and Phototherapy. The existing gold standard, Total Serum Bilirubin (TSB) Nomogram is not sufficient and the use of the DAT or Coombs test is not an accurate predictor for hemolysis. A second, new standard that involves measuring the ETCOc of a newborn in the first 24 hours has been proven to more accurately confirm the presence or absence of hemolysis.
In 2015, Dr. Robert Christensen made a reference about ETCO screening that is was a "Crystal Ball." This was a practrical, non-invasive, in expensive and rapid bedside way to tell which jaundice neonates are headed towards hemolytic jaundice.
According to American Academy of Pediatrics, "ETCOc is the only clinical test that provides a direct measurement of the rate of bilirurbn production. ETCO levels can confirm the presence or absence of hemolysis.
Capnia will introduce several studies that highlight the value in using ETCO monitoring to help improve outcomes while lowering costs. These studies will include the testing of neonates in the well nursery for hyperbilirubinemia to see who needs phototherapy, how the use of ETCO will decrease the use of phototherapy thus reducing the risk of readmission, and how the use of ETCO monitoring is a better than DAT as a screening tool for hemolysis.